SARS-CoV-2病毒持久性(VIPER)研究调查了血浆中持久的SARS-CoV-2RNA的存在,凳子,尿液,和COVID-19幸存者的鼻咽样本。分析血浆中SARS-CoV-2RNA逆转录聚合酶链反应(RT-PCR)的存在,凳子,尿液,有COVID-19后症状的COVID-19幸存者和无COVID-19后症状的比较组的鼻咽拭子样本按年龄匹配,性别,体重指数和疫苗接种状况。参与者自我报告存在任何COVID后症状(定义为在初次感染后3个月内开始的症状)。57(57.9%的女性,年龄:51.1,标准差[SD]:10.4岁)先前住院的COVID-19幸存者患有COVID后症状和55(56.4%的女性,年龄:50.0,标准差:12.8岁)在出院后27个月(标准差7.5)和26个月(标准差8.7)评估了过去有SARS-CoV-2感染而没有COVID后症状的匹配个体,分别。SARS-CoV-2RNA的存在在三个患有COVID后症状的患者的鼻咽样本中(5.2%),但在血浆中未发现,凳子,或尿液样本。因此,在任何没有COVID后症状的幸存者样本中均未发现SARS-CoV-2RNA。COVID后最常见的症状包括疲劳(93%),呼吸困难,和痛苦(两者,87.7%)。这项研究没有在血浆中发现SARS-CoV-2RNA,凳子,或者尿液样本,感染后2年。在鼻咽样本中SARS-CoV-2RNA的患病率为5.2%,提示潜在的活动性或近期的再感染,在有COVID后症状的患者中发现。这些结果不支持血浆中SARS-CoV-2RNA之间的关联。凳子,尿液,或招募人群的鼻咽拭子样本和COVID后症状。
The SARS-CoV-2 VIrus PERsistence (VIPER) study investigated the presence of long-lasting SARS-CoV-2 RNA in plasma, stool, urine, and nasopharyngeal samples in COVID-19 survivors. The presence of SARS-CoV-2 RNA reverse transcription polymerase chain reactions (RT-PCR) were analyzed within plasma, stool, urine, and nasopharyngeal swab samples in COVID-19 survivors with post-COVID symptoms and a comparison group of COVID-19 survivors without post-COVID symptoms matched by age, sex, body mass index and vaccination status. Participants self-reported the presence of any post-COVID symptom (defined as a symptom that started no later than 3 months after the initial infection). Fifty-seven (57.9% women, age: 51.1, standard deviation [SD]: 10.4 years) previously hospitalized COVID-19 survivors with post-COVID symptoms and 55 (56.4% women, age: 50.0, SD: 12.8 years) matched individuals who had a past SARS-CoV-2 infection without post-COVID symptoms were evaluated 27 (SD 7.5) and 26 (SD 8.7) months after hospital discharge, respectively. The presence of SARS-CoV-2 RNA was identified in three nasopharyngeal samples of patients with post-COVID symptoms (5.2%) but not in plasma, stool, or urine samples. Thus, SARS-CoV-2 RNA was not identified in any sample of survivors without post-COVID symptoms. The most prevalent post-COVID symptoms consisted of fatigue (93%), dyspnea, and pain (both, 87.7%). This study did not find SARS-CoV-2 RNA in plasma, stool, or urine samples, 2 years after the infection. A prevalence of 5.2% of SARS-CoV-2 RNA in nasopharyngeal samples, suggesting a potential active or recent reinfection, was found in patients with post-COVID symptoms. These results do not support the association between SARS-CoV-2 RNA in plasma, stool, urine, or nasopharyngeal swab samples and post-COVID symptomatology in the recruited population.